Compare Enveric Biosciences Inc (ENVB) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.66 (market cap $94.46M). The key difference: T-Rex 2X Inverse MSTR Daily Target ETF is far larger — about 13.9× Enveric Biosciences Inc's market cap, and T-Rex 2X Inverse MSTR Daily Target ETF is more actively traded (104,717,733 versus 64,867). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| ENVB | MSTZ | |
|---|---|---|
Market Cap | $6.80M | $94.46M |
Volume | 64,867 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $10.80 | $27.92 |
52-Week Low | $1.27 | $2.29 |
Typical Hold Time | 14 Days | 8 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
MSTZ is trading at $2.66, up 13.43% today, but technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. Key financial ratios such as P/E, P/S, and P/B are unavailable, limiting fundamental clarity. The stock's recent mention in ETF Trends (September 15, 2026) highlights its inclusion in leveraged ETF discussions, though this reflects market volatility rather than company-specific news.
The outlook is cautious due to weak technicals and missing fundamental data. Risks include high volatility from leveraged ETF exposure and lack of transparent financials. Investors should seek updated SEC filings for earnings and valuation metrics before considering a position, as current data gaps hinder a reliable assessment of growth or stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
